Table 3 Change in quality of life and daytime sleepiness between D0 and D30
D30 – D0 | % of patients achieving MCID* | |||
|---|---|---|---|---|
Mean ± SD (N) | Whole cohort | Rhinitis alone | Rhinoconjunctivitis | |
Quality of life | ||||
Mini-RQLQ score (from 0 to 6) | ||||
Global | −1.57 ± 1.51 (677) | 72% | 69% | 72% |
Nasal | −2.12 ± 1.84 (675) | 77% | 81% | 76% |
Ocular | −1.23 ± 1.76 (673) | 56% | 16% | 73% |
Activity | −1.65 ± 1.77 (676) | 72% | 75% | 71% |
Others | −1.43 ± 1.50 (675) | 71% | 67% | 72% |
Global impact (visual analog scale from 0 to 10) | −2.82 ± 3.12 (649) | 65% | 73% | 62% |
Daytime sleepiness | ||||
Epworth scale (visual analog scale from 0 to 10) | −2.18 ± 5.01 (660) | |||